The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors:  A Children's Oncology Group study.
Rochelle Bagatell
No relevant relationships to disclose
Robin Elizabeth Norris
No relevant relationships to disclose
Ashish M Ingle
No relevant relationships to disclose
Charlotte H Ahern
No relevant relationships to disclose
Jennifer Saggio
No relevant relationships to disclose
Anthony Little
No relevant relationships to disclose
Brenda Weigel
No relevant relationships to disclose
Susan Blaney
No relevant relationships to disclose